Nordic Nanovector
Kjelsåsveien 168 B
Oslo
0884
Tel: 47-22-18-33-01
Fax: 47-22-58-00-07
Website: http://www.nordicnanovector.no/
Email: mail@nordicnanovector.no
343 articles about Nordic Nanovector
-
Nordic Nanovector: Share Capital Increase Registered
8/30/2017
-
Nordic Nanovector - Results For Second Quarter And First Half Year 2017
8/23/2017
-
Nordic Nanovector: Invitation To Second Quarter 2017 Results Presentation And Webcast
8/16/2017
-
Nordic Nanovector Appoints Dr. Reza Safaei As Head Of Medical Affairs
8/2/2017
-
Nordic Nanovector: Increase Of Share Capital/Mandatory Notification Of Trade
7/10/2017
-
Nordic Nanovector: Mandatory Notification Of Trade - Primary Insider
7/5/2017
-
Nordic Nanovector: Mandatory Notification Of Trade - Primary Insider
6/22/2017
-
Nordic Nanovector Release: Single Dose Betalutin Continues To Show Promising Efficacy And Safety In Recurrent Indolent NHL Patients
6/14/2017
-
Nordic Nanovector Release: Invitation To Conference Call For Updated Clinical Trial Results Reported At The International Conference On Malignant Lymphoma
6/13/2017
-
Nordic Nanovector To Be Included In Oslo Børs OBX Index
6/9/2017
-
Nordic Nanovector Release: Accepted Abstract By ICML With Updated Results From Phase I/II Trial Of Betalutin In NHL Is Now Available On-Line
6/8/2017
-
Nordic Nanovector: Allocation Of Restricted Stock Units (RSUs) To The Board Of Directors
6/2/2017
-
Nordic Nanovector - Results For First Quarter 2017
5/24/2017
-
Nordic Nanovector Release: Safety Review Committee Approves The Continued Evaluation Of The 20 Mbq/Kg Betalutin With 100 Mg/M2 Lilotomab Regimen In Phase ll Cohort In NHL
5/19/2017
-
Nordic Nanovector: Invitation To First Quarter 2017 Results Presentation And Webcast
5/16/2017
-
Nordic Nanovector: Notice Of Annual General Meeting On 24 May 2017
5/2/2017
-
Nordic Nanovector Release: Updated Results From Phase I/II Trial Of Betalutin In NHL Accepted For Presentation At The International Conference On Malignant Lymphoma In June
4/28/2017
-
Nordic Nanovector - Financial Calendar
3/27/2017
-
Nordic Nanovector Publishes Annual Report 2016
3/24/2017
-
Nordic Nanovector Announces First Patient Dosed In Phase I Study Of Betalutin In Diffuse Large B-Cell Lymphoma (DLBCL), An Aggressive Form Of NHL
3/17/2017